US Patent

US7977324 — Process for preparing malathion for pharmaceutical use

Formulation · Assigned to Taro Pharmaceuticals North America Inc · Expires 2026-08-14 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a process for preparing a highly pure form of malathion with reduced toxic impurities that is also storage stable.

USPTO Abstract

The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.

Drugs covered by this patent

Patent Metadata

Patent number
US7977324
Jurisdiction
US
Classification
Formulation
Expires
2026-08-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Taro Pharmaceuticals North America Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.